Not All Patients Respond To Treatment With Atuzaginstat... This is the undebatable fact. But what it means that "not to reach the level of statistically significance"? It means that for the dose cohort the probaility of the dosed patients to have results like those in placebo cohorts is lower than 5%. The dispertion about the … Continue reading What Next With Cortexyme’s Atuzaginstat?
Month: October 2021
What To Expect from $CRTX and Atuzaginstat at CTAD 2021 $AVXL $SAVA
An Illustration.... X-axis is in weeks of dosing, y-axis is in MMSE points and the number 30 represents the highest score. HowI Got There.... I took the best four patients who never declined from the group of the Superperformers from phase 2a and calculated their baseline average and then their changes in time (weeks) on … Continue reading What To Expect from $CRTX and Atuzaginstat at CTAD 2021 $AVXL $SAVA
Why You Should Count On Cortexyme To Deliver The Alzheimer’s Drug! $CRTX
Jitters of The Biotech Investors and Their Cure In most PRs companies give some measure of improvement of patients, with the number of subject and the p-values. The certainty of the improvemnts are judged mostely throught the prism of p-values as it is a number with a threshold once attained a semblence of certainty is … Continue reading Why You Should Count On Cortexyme To Deliver The Alzheimer’s Drug! $CRTX